Renovacor
Kumar Dhanasekharan, Ph.D. is the Senior Vice President of Technical Operations at Renovacor. Dr. Dhanasekharan has over 20 years of CMC development and manufacturing experience across complex protein therapeutics, monoclonal antibodies, and in recent years, AAV gene therapies. Dr. Dhanasekharan has held various executive and technical operations leadership roles in the biopharma industry, including SwanBio, Amicus, Catalent, Genzyme, Sanofi spanning early phase, late phase, and commercial programs leading them successfully through IND, comparability assessments, tech transfers, and BLA.
Dr. Dhanasekharan received a Ph.D. from Rutgers University and a Bachelors in Chemical Engineering from the Indian Institute of Technology (IIT) Madras (Chennai), India. He is well-published in the field with many conference presentations and peer-reviewed publications.
This person is not in any offices
Renovacor
Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system (“CNS”) diseases resulting from BAG3 gene variants, today announced the appointment of Marc Semigran, M.D., as chief medical officer of Renovacor.